Fengmin Zhao

发表

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)

G. Babiera, T. Julian, G. Sledge, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

S. Kalnicki, J. Palefsky, A. Onitilo, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

A. Giobbie-Hurder, G. Freeman, G. Dranoff, 2017, Cancer Immunology Research.

Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer

G. Sledge, R. Carlos, K. Miller, 2020, Cancer medicine.

Symptom burden among young adults with breast or colorectal cancer

M. Fisch, J. Salsman, L. Wagner, 2014, Cancer.

Predictors of significant worsening of patient‐reported fatigue over a 1‐month timeframe in ambulatory patients with common solid tumors

C. Cleeland, D. Cella, A. O'Mara, 2014, Cancer.

Surrogate End Points and Their Validation in Oncology Clinical Trials.

Fengmin Zhao, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Management and Research Dovepress

J. Manola, D. Cella, T. Rich, 2022 .

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805

J. Manola, D. Cella, R. DiPaola, 2018, Quality of Life Research.

Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables.

J. Manola, L. Minasian, T. Deshields, 2017, Journal of pain and symptom management.

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

R. Advani, R. Gascoyne, T. Habermann, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

R. Gray, D. Cella, I. Gareen, 2021, Cancer.

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

G. T. Budd, M. Burkard, A. Onitilo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.

E. Perez, S. Martino, G. Sledge, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients

R. Gray, D. Cella, Shaji K. Kumar, 2022, Blood Cancer Journal.

Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).

A. Benson, B. Miedema, S. Hamilton, 2022, Annals of surgical oncology.

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced an

M. Atkins, J. Kirkwood, L. Butterfield, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S6-2: Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole.

G. Sledge, D. Cella, P. Goss, 2011 .

Reply to T. Shimoi et al and Y. Shimanuki et al.

W. Symmans, A. Wolff, A. DeMichele, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?

D. Cella, E. Ip, S. Shaunfield, 2022, Supportive Care in Cancer.

Cancer Outcomes in DCIS Patients Without Locoregional Treatment.

Lars J. Grimm, Ruth Etzioni, L. Grimm, 2019, Journal of the National Cancer Institute.

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

W. Symmans, A. Wolff, A. DeMichele, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Management and Research Dovepress

J. Manola, D. Cella, T. Rich, 2022 .

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

J. Manola, B. Ramaswamy, A. Wolff, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor – Positive , Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy : Results of PrE 0102

J. Manola, B. Ramaswamy, A. Wolff, 2018 .

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

K. Flaherty, J. Kirkwood, K. Nathanson, 2014, Clinical Cancer Research.

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

M. Atkins, J. Kirkwood, L. Butterfield, 2017, Clinical Cancer Research.

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.

E. Perez, S. Martino, G. Sledge, 2012, Journal of the National Cancer Institute.

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

E. Perez, S. Martino, G. Sledge, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

R. Gray, K. Flaherty, L. Rubinstein, 2020, Clinical Cancer Research.

Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.

Mark S. Anderson, Ajay S. Gulati, J. Kirkwood, 2017, JCI insight.

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

J. Manola, D. Cella, R. DiPaola, 2018, Supportive Care in Cancer.

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

G. Sledge, Molin Wang, J. Sparano, 2017, Breast Cancer Research and Treatment.

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

R. Gray, K. Flaherty, L. Rubinstein, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

K. Flaherty, J. Kirkwood, K. Nathanson, 2013, PloS one.

Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors

David Cella, Fengmin Zhao, C. Cleeland, 2014, Cancer.

The symptom burden of cancer: Evidence for a core set of cancer‐related and treatment‐related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study

J. Sloan, C. Cleeland, T. Mendoza, 2013, Cancer.

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

G. Babiera, T. Julian, G. Sledge, 2020 .

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation.

P. Catalano, A. Benson, N. Petrelli, 2016 .

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.

K. Flaherty, M. Atkins, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

K. Flaherty, J. Kirkwood, K. Nathanson, 2015, Clinical Cancer Research.

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

J. Kirkwood, L. Butterfield, C. Slingluff, 2013, Clinical Cancer Research.

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

S. Martino, N. Robert, D. Cella, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Daniel L. Koller, Lang Li, G. Sledge, 2015, Clinical Cancer Research.

Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer

E. Perez, S. Martino, G. Sledge, 2012, Cancer.

Determinants of pain severity changes in ambulatory patients with cancer: an analysis from Eastern Cooperative Oncology Group trial E2Z02.

Fengmin Zhao, C. Cleeland, J. Cleary, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).

P. Catalano, N. Petrelli, J. Sloan, 2019, The oncologist.

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

R. Gray, T. Shanafelt, D. Cella, 2020 .

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

T. Whelan, G. Sledge, D. Cella, 2018, Breast Cancer Research and Treatment.

Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches

D. Cescon, A. DeMichele, K. Smith, 2022, Frontiers in Oncology.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2018, npj Breast Cancer.

The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.

C. Cleeland, T. Mendoza, L. Patrick-Miller, 2013, Clinical breast cancer.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2017, npj Breast Cancer.

Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study.

C. Loprinzi, M. Fisch, J. Brell, 2015, Journal of pain and symptom management.

Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer

C. Loprinzi, M. Fisch, J. Brell, 2015, Journal of Cancer Survivorship.

The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group.

C. Cleeland, T. Mendoza, L. Patrick-Miller, 2014, Clinical genitourinary cancer.

Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors

J. Manola, W. Pirl, M. Fisch, 2015, Psycho-oncology.

Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer.

W. Symmans, B. Leyland-Jones, V. Bossuyt, 2021, Clinical chemistry.

Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

D. Cella, T. Owonikoko, S. Ramalingam, 2020, Cancer medicine.

Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2015 .

Association between patients' perception of the comorbidity burden and symptoms in outpatients with common solid tumors

J. Manola, C. Ritchie, C. Snyder, 2017, Cancer.

Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial

K. Flaherty, J. Kirkwood, K. Nathanson, 2012 .

Reply to B. Ulaş Kahya et al and A. Soran et al.

J. Sparano, Fengmin Zhao, S. Khan, 2022, Journal of Clinical Oncology.

Abstract OT2-01-04: E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

R. Gray, J. Sparano, A. Tevaarwerk, 2016 .

Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer

E. Perez, S. Martino, G. Sledge, 2015 .

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

J. Kirkwood, L. Butterfield, C. Slingluff, 2013, Clinical Cancer Research.

Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer

E. Perez, S. Martino, G. Sledge, 2012, Cancer.

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Daniel L. Koller, Lang Li, G. Sledge, 2015, Clinical Cancer Research.

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805

J. Manola, D. Cella, R. DiPaola, 2018, Quality of Life Research.

Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies

R. Gray, W. Curran, S. Mandrekar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

J. Manola, D. Cella, R. DiPaola, 2018, Supportive Care in Cancer.

Cancer Management and Research Dovepress

J. Manola, D. Cella, T. Rich, 2022 .

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

M. Atkins, J. Kirkwood, L. Butterfield, 2017, Clinical Cancer Research.